Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
My Account
Do not call
En
Divi's Laboratories Ltd. Share Price
Day's Range
Day's Range
Low
₹6,681.50
High
₹6,759.50
Price Summary
| Previous Close | ₹6,695.50 |
|---|---|
| Day's Range | ₹6,681.50 - ₹6,759.50 |
| Open | ₹6,730.00 |
| 52 Week Range | ₹5,636.50 - ₹7,071.50 |
| Volume | 46,088 |
| Market Cap | ₹0.18 |
| Previous Close | ₹6,701.95 |
|---|---|
| Day's Range | ₹6,680.05 - ₹6,766.35 |
| Open | ₹6,766.35 |
| 52 Week Range | ₹5,637.50 - ₹7,077.70 |
| Volume | 2,012 |
| Market Cap | ₹0.18 |
Stocks Summary
| Trade Value ( ₹ in Lacs) | 3,085.82 |
|---|---|
| Market Cap (₹ in Mn) | 0.18 |
| Dividend Yield(%) | 0.45 |
| Price/Earning (TTM) | 69.40 |
| TTM EPS (₹) | 96.73 |
| P/E Ratio | 69.83 |
| Book Value(₹) | 10.63 |
| PAT Margin (%) | 23.29 |
| Face Value (₹) | 2.00 |
| ROCE(%) | 20.45 |
| Trade Value ( ₹ in Lacs) | 134.84 |
|---|---|
| Market Cap (₹ in Mn) | 0.18 |
| Dividend Yield(%) | 0.45 |
| Price/Earning (TTM) | 69.40 |
| TTM EPS (₹) | 96.73 |
| P/E Ratio | 69.83 |
| Book Value(₹) | 10.63 |
| PAT Margin (%) | 23.29 |
| Face Value (₹) | 2.00 |
| ROCE(%) | 20.45 |
Financials
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 25360.0 | 91980.0 |
| Expenses | N/A | N/A |
| PBT | 8610.0 | 29290.0 |
| Operating profit | 0.0 | 0.0 |
| Net profit | 6670.0 | 22090.0 |
About Divi's Laboratories Ltd.
| Founded | 1990 |
|---|---|
| Managing Director | Murali K Divi |
| NSE Symbol | DIVISLAB |
Peer Comparision
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,32,036.25 | 1,816.65 | 1,548.00 - 1,548.00 |
| Divi's Laboratories Ltd. | 1,78,218.35 | 6,701.95 | 5,636.50 - 5,636.50 |
| Torrent Pharmaceuticals Ltd. | 1,51,098.97 | 4,453.20 | 3,140.10 - 3,140.10 |
| Apollo Hospitals Enterprise Ltd. | 1,20,631.73 | 8,454.00 | 6,696.50 - 6,696.50 |
| Cipla Ltd. | 1,10,896.97 | 1,362.05 | 1,165.70 - 1,165.70 |
| Zydus Lifesciences Ltd. | 1,08,512.27 | 1,068.20 | 835.50 - 835.50 |
| Dr. Reddy's Laboratories Ltd. | 1,06,591.41 | 1,270.80 | 1,148.40 - 1,148.40 |
| Lupin Ltd. | 1,04,111.85 | 2,272.35 | 1,836.80 - 1,836.80 |
| Max Healthcare Institute Ltd. | 99,630.97 | 1,025.30 | 903.00 - 903.00 |
| Mankind Pharma Ltd. | 97,332.83 | 2,378.00 | 1,909.70 - 1,909.70 |
No Records Found
Latest News
Divis Laboratories informs about deduction of Income tax at source from payment of dividend
Divi’s Laboratories informs about closing of trading window
Pursuant to the Company’s Code of Conduct to Regulate, Monitor and Report Trading by Designated Persons, Immediate Relatives of Designated Persons and Insiders (the Code), Divi’s Laboratories has informed that the Trading Window for dealing in securities of the Company will remain closed from April 01, 2026 till 48 hours after the declaration of audited financial results of the Company for the quarter and financial year ended March 31, 2026. The date of Board meeting for declaration of the audited financial results of the Company for the quarter and financial year ended March 31,2026, will be intimated in due course.
The above information is a part of company’s filings submitted to BSE.
Glenmark Pharmaceuticals informs about press release
Glenmark Pharmaceuticals has informed that, Glenmark Pharmaceuticals Inc., USA (Glenmark) today announced the launch of Methylene Blue Injection USP, 50 mg/10 mL (5 mg/mL) Single‐Dose Vial. Glenmark’s Methylene Blue Injection USP is bioequivalent and therapeutically equivalent to the reference listed drug, ProvayBlue® Injection, 50 mg/10 mL (5 mg/mL), of Provepharm SAS [NDA 204630]. According to IQVIA® sales data for the 12‐month period ending April 2026, the ProvayBlue® Injection, 50 mg/10 mL (5 mg/mL) market achieved annual sales of approximately $19.0 million. The company has attached media release.
3The above information is a part of company’s filings submitted to BSE.
Hannah Joseph Hospital submits investor presentation
Pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Hannah Joseph Hospital has submitted the Investor Presentation of the Company. Further it has informed that the aforesaid presentation does not contain any Unpublished Price Sensitive Information (UPSI). The Investor Presentation is also available on the Company's website at www: hannahjosephhospital.com.
The above information is a part of company’s filings submitted to BSE.
Zydus Lifesciences informs about press release
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The current share price of Divi's Laboratories Ltd. is ₹6,695.50 as of 2026-06-17.
The market capitalisation of Divi's Laboratories Ltd. is ₹178,218.35 as of 2026-06-16.
The 1-year return of Divi's Laboratories Ltd. is -17.00% as of 2026-06-17.
The P/E ratio of Divi's Laboratories Ltd. is 69.83 as of 2026-06-17.
The 52-week high and low of Divi's Laboratories Ltd. are ₹7,071.50 and ₹5,636.50, respectively, as of 2026-06-17.
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
